Table 3.

Univariate Analysis of 10-Year Kaplan-Meier Locoregional Recurrence-Free Outcomes in the No-PMRT Group

Characteristic	Variable	n	LRR-free survival (95% CI)	p-value
All patients		924
Gender	Female	898	0.93 (0.91–0.95)	0.61
	Male	26	0.94 (0.67–0.99)
Age	<40	147	0.81 (0.73–0.87)	<.0001
	40–50	264	0.93 (0.90–0.96)
	50–60	232	0.95 (0.91–0.97)
	60–70	150	0.98 (0.93–0.99)
	>70	131	0.95 (0.87–0.98)
Tumor Size	0.1–2.0 cm	638	0.94 (0.92–0.96)	0.085
	2.1–5.0 cm	449	0.91 (0.87–0.94)
Histological Grade	I	20	1	0.053
	II	204	0.95 (0.91–0.98)
	III	572	0.91 (0.88–0.93)
Nuclear Grade	I	20	1	0.010
	II	366	0.95 (0.92–0.97)
	III	365	0.90 (0.85–0.93)
Extensive Intraductal Component	Yes	243	0.92 (0.88–0.95)	0.39
	No	678	0.93 (0.91–0.95)
Multifocal/Multicentric	Yes	390	0.93 (0.90–0.95)	0.89
	No	534	0.93 (0.90–0.95)
Lymphovascular Invasion	Yes	408	0.88 (0.85–0.91)	<.0001
	No	516	0.97 (0.94–0.98)
Extracapsular Extension	Yes	115	0.95 (0.88–0.98)	0.43
	No	809	0.93 (0.91–0.94)
Axillary Procedure	SLNB Only	60	0.89 (0.77–0.96)	0.47
	ALND	864	0.93 (0.91–0.95)
Number of Positive Nodes	1	577	0.94 (0.91–0.96)	0.099
	2	242	0.93 (0.89–0.96)
	3	105	0.87 (0.78–0.93)
Size of Axillary Nodal Metastasis	Macroscopic	661	0.91 (0.89–0.94)	0.033
	Microscopic	259	0.96 (0.92–0.98)
Estrogen Receptor	Positive	710	0.93 (0.91–0.95)	0.60
	Negative	197	0.93 (0.88–0.96)
Progesterone Receptor	Positive	552	0.94 (0.91–0.96)	0.25
	Negative	358	0.92 (0.88–0.94)

PMRT, postmastectomy radiation therapy; LRR, locoregional recurrence; CI, confidence interval; SLNB, sentinel lymph node biopsy; ALND; axillary lymph node dissection